NNVC NanoViricides, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

NNVC [AMEX]

NanoViricides, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.72	Insider Own	14.97%	Shs Outstand	6.52M	Perf Week	1.60%
Market Cap	65.62M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	6.40M	Perf Month	-18.61%
Income	-13.80M	PEG	-	EPS next Q	-	Inst Own	22.30%	Short Float	10.52%	Perf Quarter	0.63%
Sales	-	P/S	-	EPS this Y	11.10%	Inst Trans	24.35%	Short Ratio	0.46	Perf Half Y	-8.78%
Book/sh	2.20	P/B	2.88	EPS next Y	-	ROA	-103.30%	Target Price	-	Perf Year	37.83%
Cash/sh	0.59	P/C	10.76	EPS next 5Y	-	ROE	-132.00%	52W Range	1.27 - 19.20	Perf YTD	152.59%
Dividend	-	P/FCF	-	EPS past 5Y	15.10%	ROI	-	52W High	-66.98%	Beta	0.91
Dividend %	-	Quick Ratio	2.90	Sales past 5Y	-	Gross Margin	-	52W Low	398.70%	ATR	0.52
Employees	17	Current Ratio	2.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	45.73	Volatility	4.06% 6.95%
Optionable	Yes	Debt/Eq	0.08	EPS Q/Q	-108.50%	Profit Margin	-	Rel Volume	0.24	Prev Close	6.16
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	1.47M	Price	6.34
Recom	-	SMA20	-4.79%	SMA50	-9.16%	SMA200	8.27%	Volume	355,742	Change	2.92%

Feb-11-15

Initiated

Midtown Partners

Strong Buy

$5.30

Aug-06-20 01:43PM	LD Micro: Announces Preliminary List of Presenters for the LD-500 ACCESSWIRE
Jul-23-20 11:48AM	NanoViricides, Inc. Raises $11.5 Million Through Public Offering After Positive Test Results For COVID-19 Drug Newsfile
Jul-21-20 06:15AM	NanoViricides to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit Today, July 21, 2020 ACCESSWIRE
Jul-20-20 06:10PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds NanoViricides (NNVC) Investors of Proprietary Investigation into Possible Securities Law Violations, Encourages Investors and Persons Who May be Able to Assist Investigation to Contact Firm GlobeNewswire
Jul-16-20 03:16PM	Glancy Prongay & Murray LLP, a National Class Action Law Firm, Announces Investigation of NanoViricides, Inc. (NNVC) on Behalf of Investors Business Wire
10:52AM	NanoViricides, Inc. Investors Who Purchased NNVC Securities After January 2020 And Suffered Losses Greater Than $50,000 Encouraged To Contact Kehoe Law Firm, P.C. GlobeNewswire
Jul-13-20 06:30AM	NanoViricides Closes On $11.5 Million Underwritten Public Offering of Common Stock ACCESSWIRE
Jul-09-20 06:15AM	NanoViricides Prices $10.0 Million Underwritten Public Offering of Common Stock ACCESSWIRE -10.56%
Jul-08-20 05:55PM	Nanoviricides Commences Underwritten Public Offering of Common Stock ACCESSWIRE +25.87%
05:50PM	Covid-19 Research Update: The Stars and the Question Marks GuruFocus.com
06:15AM	Safety and Tolerability of Anti-Coronavirus Drug Candidates Observed in an Animal Model Further Advances NanoViricides SARS-CoV-2 Therapeutics Program ACCESSWIRE
Jun-30-20 06:15AM	NanoViricides Announces Addition to Russell Microcap(R) Index ACCESSWIRE
Jun-25-20 11:05AM	NanoViricides: Sufficient Funding for Covid-19 Research GuruFocus.com +20.11%
Jun-23-20 06:15AM	NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2020 - Has Sufficient Cash, Progress on New Coronavirus Drug Program and the Lead HerpeCide(TM) Drug Candidate IND Application ACCESSWIRE +11.42%
Jun-09-20 07:46AM	The Daily Biotech Pulse: Soleno Flunks Late-Stage Study, Sanofi Strikes Breast Cancer Partnership, NanoViricides Shortlists Coronavirus Treatment Candidates Benzinga +9.16%
06:15AM	NanoViricides Signs Memorandum of Understanding for Human Coronavirus Drug Development License ACCESSWIRE
May-26-20 06:15AM	NanoViricides Announces Completion of $10.2 Million Registered Direct Offering - Funds to Accelerate COVID-19 Drug Program and HerpeCide Program ACCESSWIRE
May-21-20 08:30AM	NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering ACCESSWIRE -15.73%
May-20-20 06:15AM	Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus ACCESSWIRE -5.80%
May-18-20 06:15AM	Honorable Ex-Congressman Todd Rokita Joins the Board of Directors of NanoViricides, Inc. ACCESSWIRE +5.30%
May-13-20 10:12AM	Company News for May 13, 2020 Zacks +15.57%
May-12-20 12:57PM	NanoViricides: New Covid-19 Drug Candidates Could Boost Performance GuruFocus.com +28.27%
06:15AM	NanoViricides Develops Highly Effective Broad-Spectrum Drug Candidates Against Coronaviruses ACCESSWIRE
May-04-20 06:15AM	NanoViricides Signs Confidential Disclosure Agreement with International Pharmaceutical Company to Explore Collaborating on its COVID-19 Program ACCESSWIRE +14.71%
Apr-29-20 06:15AM	NanoViricides Presentation on COVID-19 and Shingles Drug Development Update at the Planet MicroCap Showcase Virtual Investor Conference 2020 is Now Available ACCESSWIRE -6.29%
Apr-21-20 02:00PM	NanoViricides to Present COVID-19 and Shingles Drug Development Update at the Planet MicroCap Showcase Virtual Investor Conference 2020 on April 22nd ACCESSWIRE +33.62%
Apr-13-20 06:15AM	NanoViricides President Dr. Anil Diwan was Interviewed by Proactive Investors About the Companys Antiviral Drug Development Against SARS-CoV-2 to Treat COVID-19 ACCESSWIRE
Apr-07-20 02:31PM	Does NanoViricides, Inc. (NYSEMKT:NNVC) Have A High Beta? Simply Wall St.
11:49AM	NanoViricides: The Visit From Senator Blumenthal Is a Positive Development GuruFocus.com
Apr-06-20 06:15AM	U.S. Senator Richard Blumenthal Visited NanoViricides Inc. for Update on Coronavirus (COVID-19) Drug Development Efforts ACCESSWIRE
Mar-31-20 07:30AM	NanoViricides, Inc. Progress on COVID-19 Drug Encouraging Newsfile
Mar-16-20 06:15AM	Coronavirus Drug Development Update from NanoViricides, Inc. ACCESSWIRE +6.12%
Mar-14-20 10:18AM	Inovio stock rallies after company gets Gates Foundation grant to test device for coronavirus vaccine MarketWatch
Mar-13-20 05:42PM	The Coronavirus Pandemic Has Revealed Some Micro-Cap Opportunities GuruFocus.com -9.74%
Mar-09-20 02:44PM	Is Inovio Pharmaceuticals Stock the Cure for Your Portfolio? InvestorPlace -17.96%
Mar-05-20 04:11PM	NanoViricides, Inc. Reports Discovery of Broad-Spectrum Virus-Binding Ligands; Expected to Counter COVID-19 Newsfile
Feb-28-20 04:57PM	Dow, S&P 500 fall for 7th straight day; stocks suffer biggest weekly fall since 2008 MarketWatch -7.95%
Feb-25-20 03:25PM	18 Medical Stocks To Watch Amid The Coronavirus Outbreak Benzinga -13.76%
Feb-24-20 08:39AM	NanoViricides stock soars amid fears of global spread of COVID-19 MarketWatch +38.37%
08:04AM	Benzinga Pro's Top 5 Stocks To Watch For Mon., Feb. 24, 2020: NNVC, WFC, SPCE, LL, CETX Benzinga
06:15AM	NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2019 - Has Sufficient Cash, HerpeCide(TM) Drug Candidate IND Application Development in Progress ACCESSWIRE
Feb-18-20 01:01PM	The Wuhan Virus and Research-Focused Biotech Companies GuruFocus.com
Feb-12-20 06:15AM	Dr. Mak Jawadekar Joins the Board of Directors of NanoViricides, Inc. ACCESSWIRE -7.03%
Feb-10-20 07:30AM	Nanoviricides President Dr. Diwan Was Interviewed by The Varney Show on Fox Business News ACCESSWIRE +17.41%
Feb-06-20 05:50PM	Can Biotech ETFs Continue to Soar in 2020? Zacks -7.91%
Feb-04-20 07:30AM	Nanoviricides President Dr. Diwan Was Interviewed By The Kennedy Show On Fox Business News ACCESSWIRE -6.38%
Feb-03-20 02:17PM	Coronavirus update: 361 have died, there are now 11 cases in the U.S. and the case count has doubled SARS MarketWatch -35.44%
08:59AM	Benzinga Pro's Top 5 Stocks To Watch For Mon., Feb. 3, 2020: SYY, PCG, NNVC, UBER, TSLA Benzinga
Feb-01-20 10:53AM	Coronavirus update: WHO says prepare for local coronavirus outbreaks in other countries MarketWatch
Jan-31-20 09:09AM	The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO Benzinga +39.67%
Jan-30-20 06:20PM	NanoViricides Confirms It Has Been Working On A Treatment For The Novel Wuhan Coronavirus ACCESSWIRE +26.58%
10:54AM	These 4 Biotech Stocks Are the Silver Lining on the Wuhan Coronavirus GuruFocus.com
Jan-28-20 02:23PM	Coronavirus update: Vaccine stocks retreat and airport screening expands to 20 U.S. airports MarketWatch -46.84%
07:53AM	Company News For Jan 28, 2020 Zacks
Jan-27-20 04:29PM	Dow ends more than 450 points lower as spread of coronavirus quashes buying sentiment MarketWatch +86.98%
04:03PM	Stock market news live: Stocks close lower as coronavirus death toll rises Yahoo Finance
02:21PM	CDC officials say coronavirus is similar to SARS, no new U.S. cases reported MarketWatch
10:58AM	Analyst: China's coronavirus victims 'probably 10 times' higher than reported Yahoo Finance
08:43AM	Vaccine, diagnostics stocks rise again on spreading coronavirus MarketWatch
Jan-24-20 10:45PM	NanoViricides Closes on $8.625 Million Underwritten Public Offering of Common Stock ACCESSWIRE +54.48%
03:08PM	Biotech ETFs Are Not Riding the Wave from Coronavirus Panic ETF Trends
Jan-23-20 03:14PM	The latest coronavirus stock screamers: Inovio Pharmaceuticals, Co-Diagnostics MarketWatch +43.19%
01:02PM	13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak Benzinga
11:01AM	UPDATE: Vaccine stocks rise sharply as coronavirus fears mounts MarketWatch
10:18AM	3 Biotech Stocks Likely to Gain as Coronavirus Spreads Zacks
09:51AM	The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech Zacks
06:54AM	Vaccine makers tap into virus-driven rally to raise money MarketWatch
Jan-22-20 09:09AM	Benzinga Pro's Top 5 Stocks To Watch For Wed., Jan. 22, 2020: NFLX, TSLA, NNVC, SKT, SPCE Benzinga -55.06%
08:12AM	Coronavirus Infects Wall Street: Stocks to Gain & Lose Zacks
Jan-21-20 08:35PM	NanoViricides Prices $7.5 Million Underwritten Public Offering of Common Stock ACCESSWIRE +152.98%
02:40PM	Experimental vaccine stocks jump on concerns about new virus in China MarketWatch
Jan-09-20 08:00AM	NanoViricides Successfully Completes Required Genetic Toxicology Testing of Lead Drug Candidate NV-HHV-101 ACCESSWIRE +17.08%
Jan-07-20 08:30AM	NanoViricides Has Initiated Genetic Toxicology Testing Required for an IND for Its Drug Candidate ACCESSWIRE -11.64%
Jan-06-20 07:30AM	NanoViricides Receives Cash Infusion of $2.25 Million ACCESSWIRE -6.47%
Dec-17-19 08:30AM	NanoViricides Inc.: Upcoming Human Clinical Trials Create Opportunity for Innovation ACCESSWIRE -7.96%
Dec-09-19 08:30AM	NanoViricides President Dr. Anil Diwan Provides Responses to Shareholder Questions at the Annual Meeting of Shareholders ACCESSWIRE
Dec-06-19 08:30AM	NanoViricides Annual Meeting of Shareholders to be Held on Saturday, December 7th, 2019 at the Sheraton Hotel, Stamford, CT ACCESSWIRE -7.20%
Dec-03-19 07:30AM	NanoViricides Founder Dr. Diwan Provides $2,000,000 Loan Commitment to the Company ACCESSWIRE -11.16%
Dec-02-19 07:30AM	NanoViricides Has Initiated Required Safety Pharmacology Assessment of Lead Drug Candidate towards IND ACCESSWIRE -5.63%
Nov-19-19 09:00AM	NanoViricides Files Quarterly Report for Period Ending September 30, 2019 - HerpeCide Drug Candidate IND Enabling Studies Update, Progressing Towards Clinical Trials ACCESSWIRE +8.72%
Nov-04-19 07:30AM	NanoViricides Completes Licensing for VZV Field which Includes Shingles Drug Development ACCESSWIRE
Oct-31-19 07:30AM	NanoViricides Initiates Required Dermal Sensitization and Ocular Irritation Testing of Lead Drug Candidate towards IND ACCESSWIRE
Oct-25-19 09:20AM	NanoViricides, Inc., Builds Promising Pipeline Targeting a Multi-Billion Dollar Market for Herpes and Shingles ACCESSWIRE +13.70%
Oct-09-19 07:30AM	NanoViricides Has Initiated Bio-analytical Studies as Part of IND-Enabling Safety and Toxicology Studies of Lead Candidate NV-HHV-101 ACCESSWIRE
Oct-03-19 07:30AM	NanoViricides is Creating Nanomedicines to Develop Antiviral Therapies to Combat Shingles and Herpes Viruses Interviewing with Proactive Investors, President & Chairman Anil R. Diwan Outlines the History and Cutting Edge Technology Driving Proprietary Therapies ACCESSWIRE -16.50%
Sep-30-19 07:30AM	NanoViricides, Inc. Files Form S-1 Registration Statement ACCESSWIRE -21.15%
Sep-20-19 11:33AM	What Percentage Of NanoViricides, Inc. (NYSEMKT:NNVC) Shares Do Insiders Own? Simply Wall St. +5.43%
Sep-12-19 09:00AM	NanoViricides, Inc. Announces One-for-Twenty Reverse Stock Split PR Newswire -7.04%
Aug-26-19 07:30AM	NanoViricides, Inc. Has Filed its Annual Report, Company Advancing Rapidly Towards First IND PR Newswire
Aug-05-19 07:00AM	NanoViricides Reports Its First Drug Candidate is on Track with GLP Safety/Toxicology Studies toward Human Clinical Trials PR Newswire
Jul-11-19 10:10AM	Does The NanoViricides, Inc. (NYSEMKT:NNVC) Share Price Fall With The Market? Simply Wall St.
Jun-10-19 07:00AM	NanoViricides, Inc. Appoints Dr. Mark Day to its Board of Directors PR Newswire
Jun-03-19 07:00AM	NanoViricides has Received Favorable FDA Comments on Its Pre-IND Application for the Lead Drug Candidate PR Newswire -9.09%
May-20-19 07:00AM	NanoViricides Files Quarterly Report for Period Ending March 31, 2019 - HerpeCide Drug Candidate Pre-IND Application Submitted, Progressing Towards Clinical Trials PR Newswire
Apr-24-19 01:00PM	Some NanoViricides (NYSEMKT:NNVC) Shareholders Have Taken A Painful 92% Share Price Drop Simply Wall St.
Apr-16-19 07:00AM	NanoViricides Submits Pre-IND Briefing Documents to the US FDA PR Newswire
Apr-09-19 09:00AM	NanoViricides Provides Update on Pre-IND Meeting with the US FDA, GLP Safety/Toxicology Studies to Begin Soon, Multiple Kg Scale Drug Production Accomplished at Its Own Facility PR Newswire +7.03%
Mar-26-19 07:00AM	NanoViricides has Requested a Pre-IND Meeting with the US FDA PR Newswire -5.14%
Mar-12-19 07:00AM	NanoViricides Reports Successful Completion of Another Important Safety Study towards an IND PR Newswire
Mar-05-19 07:00AM	NanoViricides Reports Excellent Safety Profile of Its First Drug Candidate in Dermal Treatment Study PR Newswire -11.59%

NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. Its products pipeline includes HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of all types of Dengue viruses; and HIVCide that is an escape-resistant anti-HIV nanoviricide. In addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience